Story
Dyslipidemia · understanding cholesterol
Last updated
In one pass When you read a lipid panel, don't fix on the total-cholesterol line alone.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
Cholesterol · not a single number
When you read a lipid panel, don't fix on the total-cholesterol line alone. What decides whether your arteries run into trouble is how many particles in your blood can burrow into the artery wall, and how high your own overall cardiovascular risk is.
The same "bad cholesterol" number (low-density lipoprotein cholesterol, ) means something completely different in a 40-year-old who does not smoke and has normal blood pressure than in someone who has already had a heart attack: whether to treat it, and how low to push it, are not the same question. Heart attacks and strokes also tend to come not from the plaque that narrows the artery most, but from the one most likely to break open.
So a lipid result is read on three things: how many particles can burrow into the artery wall, how high your overall risk is, and how stable the plaque is.
The same "bad cholesterol" number (low-density lipoprotein cholesterol, ) means something completely different in a 40-year-old who does not smoke and has normal blood pressure than in someone who has already had a heart attack: whether to treat it, and how low to push it, are not the same question. Heart attacks and strokes also tend to come not from the plaque that narrows the artery most, but from the one most likely to break open.
So a lipid result is read on three things: how many particles can burrow into the artery wall, how high your overall risk is, and how stable the plaque is.
Numbers · What each line means, and the LDL targets
Dyslipidemia is the risk most worth managing, and the one you can actually move, for atherosclerotic cardiovascular disease (: heart attack, stroke and related conditions). So whether your lipids are high is not a matter of the total-cholesterol (TC) line alone; you have to look at the parts that actually cause disease.Each line on the report says something different. (low-density lipoprotein cholesterol) is the so-called bad cholesterol, and it has a direct causal link to artery events. (high-density lipoprotein cholesterol, the so-called good cholesterol) runs the other way, and higher is generally better, though recent evidence suggests it looks more like a bystander to risk than an active protector. High (TG) are often a sign that the body is not responding well to insulin, and they raise risk in their own right. To count all these disease-causing particles together, there are two fuller markers: non-HDL-C (total cholesterol minus HDL-C) and (apolipoprotein B). ApoB counts the particles directly, and in people with high triglycerides, diabetes or obesity it is more accurate than LDL-C (why is on the page Why particle count beats cholesterol content). Two more items are easy to miss: , lipoprotein(a), is set by your genes, so measuring it once in a lifetime is enough; and remnant cholesterol (the bit of cholesterol carried inside triglyceride-rich particles) is an extra risk on top of LDL.
How low should LDL-C go, then? Not a blanket "lower is always better"; it depends on your risk tier. Anyone who has already had an ASCVD event (heart attack, stroke), or whose diabetes has already damaged target organs, is at very high risk. People who have not had an event first estimate their 10-year ASCVD risk with ready-made tools: the US uses the PCE (pooled cohort equations), Europe uses SCORE2, and for Chinese people the locally calibrated China-PAR is recommended. On the tiers of the US AHA/ACC 2018 guideline, a 10-year risk of 20% or more (or a severe situation such as LDL-C itself ≥ 4.9 mmol/L) is high risk, 7.5–19.9% is intermediate, and below 7.5% is low (within that range the US guideline also carves out a borderline tier).
The targets below come from the European ESC/EAS 2019 guideline. It draws its risk tiers with its own method, and its cut-offs do not map one-to-one onto the US percentages above, so read it as a guide to "the higher the risk, the stricter the target":
Low risk: < 3.0 mmol/L (116 mg/dL)Moderate risk: < 2.6 mmol/L (100 mg/dL)High risk: < 1.8 mmol/L (70 mg/dL), and at least half below where you startedVery high risk: < 1.4 mmol/L (55 mg/dL), again at least half below where you started
Mechanism · Why particle count beats cholesterol content
There is a clinically useful idea the public rarely hears: what drives atherosclerosis is the number of lipoprotein particles, not how much cholesterol each particle carries. Grasp this and you can explain why some people whose looks normal still have cardiovascular events.Every cholesterol-carrying particle in the blood, such as low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) and lipoprotein(a) [], carries one protein on its surface: one particle, one ApoB. So measuring ApoB directly counts how many particles can burrow into the artery wall. LDL-C measures the total cholesterol inside those particles. If a person's particles are small and dense (common with high , diabetes and obesity), the same LDL-C number can hide far more particles. That is why people with normal LDL-C but high ApoB have their risk underestimated.
Atherosclerosis begins when these ApoB-carrying particles burrow under the inner lining of the artery (the endothelium), get oxidized, and attract macrophages that swallow them and turn into foam cells. The more particles, the more chances to get in. So particle number (ApoB) tracks the real causal chain more closely than cholesterol content (LDL-C).
In practice: for most people LDL-C and ApoB agree closely, and LDL-C is enough. But in people with high triglycerides, diabetes or obesity, or whose LDL-C is at target while their risk is still high, one ApoB test sorts the risk more accurately.
Lp(a) is another long-overlooked particle: it is set by your genes and barely moved by diet or exercise, and high Lp(a) is an independent risk factor for cardiovascular disease and for narrowing of the aortic valve (aortic stenosis). Guidelines recommend measuring it at least once in a lifetime, so you know whether you were born with a higher risk.
Chapter 2
What statins do and common worries
Statins do not flush cholesterol out of the blood. They get the liver to open more "reclaim ports" and pull the particles that burrow into artery walls out of the blood. In the largest pooled analysis, the CTT Collaboration combined 26 with about 170,000 people in the Lancet in 2010: each 1 mmol/L drop in cut major cardiovascular events by about 22% and deaths from all causes by about 10%.
Most of the online claims that "statins are toxic" do not hold up. Real side effects exist (a slightly higher diabetes risk, for example), but they are much smaller than the cardiovascular events statins prevent. Red yeast rice is not a natural substitute either: its active ingredient, monacolin K, is chemically the same molecule as lovastatin, so it carries the same side effects as a statin.
Most of the online claims that "statins are toxic" do not hold up. Real side effects exist (a slightly higher diabetes risk, for example), but they are much smaller than the cardiovascular events statins prevent. Red yeast rice is not a natural substitute either: its active ingredient, monacolin K, is chemically the same molecule as lovastatin, so it carries the same side effects as a statin.
Mechanism · How statins lower LDL cholesterol
Statins work more cleverly than most people imagine. They do not directly flush cholesterol out of the blood; they work on the liver cell's supply and demand.The liver is the body's main cholesterol factory, and the slowest step on its production line, the one that sets the pace, is run by an enzyme called HMG-CoA reductase. A statin's chemical structure mimics that enzyme's starting material, occupies it, and holds back the liver's own cholesterol production. When the liver cell senses it is short of cholesterol, it puts more low-density lipoprotein () receptors, docks that grab LDL particles, on its surface and pulls more LDL particles back out of the blood. The result: LDL particles are cleared from the blood by the liver, and LDL-C and fall together. That is why, in the CTT , each 1 mmol/L drop in LDL-C brings a steady step down in risk: what falls is exactly the particle count that burrows into artery walls.
Statins also have pleiotropic effects: they lower inflammation in the artery wall and make plaque more stable (for how inflammation and atherosclerosis are linked, see Chronic low-grade inflammation). In the trials, though, the benefit of statins was broadly proportional to how far LDL-C fell, so how much these extra effects add is still debated.
Lipid-lowering intensity comes in three tiers:
High intensity (atorvastatin 40–80 mg, or rosuvastatin 20–40 mg): LDL-C down ≥ 50%Moderate intensity: LDL-C down 30–49%Low intensity: LDL-C down < 30%
People who already have (secondary prevention) usually take high intensity; people who have not had an event (primary prevention) choose the intensity by risk tier. The point is not "I take a statin" but "I reached my target"; if you have not, the dose should go up or a second drug should be added (ezetimibe, a PCSK9 inhibitor).
Clinical · Who should take a statin
Anyone who has already had an event (heart attack, stroke, a stent) should almost always take a statin, and at high intensity. People who have not had an event go by risk (this is the approach of the US AHA/ACC guideline): of ≥ 4.9 mmol/L can be treated directly, with no need to calculate 10-year risk first; people with diabetes aged 40–75 usually take moderate intensity; and for a 10-year ASCVD risk of ≥ 7.5%, it is a shared decision with a doctor that leans toward a statin.In absolute terms (a rough estimate from the pooled effect in statin trials): in high-risk people, treating 100 people for five years prevents about 5 heart attacks or strokes. In proportional terms, the effect is similar in men and women, and in people with and without diabetes. The point is not the words "I take a statin" but reaching the target; if you have not, the dose should go up or a second drug should be added.
Myth · Common claims about statins
"Statins damage the liver": serious liver injury occurs in under 0.01% of users. Routine repeated liver tests have brought no benefit, and a mild rise in transaminases (the liver enzymes on a lab report) does not require stopping.Muscle aches (known medically as statin-associated muscle symptoms, SAMS): in randomized trials the true rate is under 5%, while observational studies make it look like 10–20%. The gap mostly comes from the nocebo effect: the more you worry about it, the more likely you are to feel the ache. Most people settle after switching to another statin or lowering the dose.
"Statins cause diabetes": this one is real, but small. As a rough estimate, about 1 extra case appears per 200 people treated for five years, against about 1 cardiovascular event prevented per 50 people, so the balance stays strongly in favor. High-intensity statins carry slightly more of this risk.
"Statins cause dementia" or "statins shorten life": neither has evidence behind it. The FDA once added a note about memory problems to the label, based on scattered case reports; later large studies did not confirm that statins cause dementia, and the CTT data show deaths from all causes going down.
Clinical · When statins truly cannot be tolerated
True statin intolerance affects under 5% of people. Most muscle aches come from the nocebo effect, or from another problem such as low vitamin D or an underactive thyroid. The fixes are a lower dose, a different statin, or taking it every other day. Coenzyme is often suggested for the aches, but Banach 2015, a pooling 6 randomized trials and 302 patients, found no significant improvement in statin-associated muscle pain or in ; more in see Coenzyme Q10 (Ubiquinone / Ubiquinol).If you really cannot reach your target, or truly cannot tolerate a statin, other drugs can take over:
Ezetimibe: reduces cholesterol absorption from the gutPCSK9 inhibitors (evolocumab, alirocumab): can lower by another 50–60% and cardiovascular events by another 15–20%; they are injected and expensiveInclisiran: a small interfering RNA (siRNA) drug given as an injection every six months; long-term outcome data are still building upBempedoic acid: does not enter muscle, which suits people who cannot tolerate statins. In the CLEAR Outcomes trial (Nissen 2023, 13,970 statin-intolerant patients), it cut major cardiovascular events by about 13%; in a subgroup analysis of people without prior events (primary prevention) the figure was about 30%, and subgroup results are only a guide. It is the first hard-outcome evidence for this groupPelacarsen, aimed at , is still in phase III trials
Monacolin K, the active ingredient in red yeast rice, is chemically lovastatin, so it carries the same side effects as a statin; impurities and content also vary from product to product, so it is not a substitute for a prescribed statin. More in see Red Yeast Rice.
Chapter 3
Mechanism · how plaque grows
Why does high "bad cholesterol" take decades to cause an event? Because atherosclerosis is a quiet build-up over decades. Lipoprotein particles carrying burrow into the artery wall, get oxidized, and draw in macrophages that swallow them and turn into foam cells, which pile up layer by layer into plaque.
What kills is not the tightest narrowing but an unstable plaque, one with a thin fibrous cap, a large fatty core and strong inflammation: when it breaks open, a clot blocks the artery on the spot, and that is a heart attack or stroke. So the key is to cut the particles getting into the artery wall early, rather than waiting until symptoms appear.
What kills is not the tightest narrowing but an unstable plaque, one with a thin fibrous cap, a large fatty core and strong inflammation: when it breaks open, a clot blocks the artery on the spot, and that is a heart attack or stroke. So the key is to cut the particles getting into the artery wall early, rather than waiting until symptoms appear.
Mechanism · Particles burrow in and draw inflammation
Step one, particles burrow into the artery wall. -carrying lipoprotein particles (mainly , low-density lipoprotein) seep from the bloodstream to beneath the endothelium, the innermost layer of cells in the artery. High blood pressure, smoking and high blood sugar damage the endothelium and make it easier for particles to get in. The more particles (the higher the ApoB), the more chances they have to get in, which is what lowering particle number is for; controlling blood pressure, not smoking and controlling blood sugar protect that lining. For blood pressure, see Hypertension.Step two, oxidation plus inflammation. The LDL that has burrowed in gets oxidized; oxidized LDL draws in the immune system, monocytes enter the inner layer of the artery and become macrophages, and the macrophages swallow the oxidized LDL and become fat-filled foam cells. This step is driven by inflammation: the Libby 2011 review describes atherosclerosis as a chronic inflammation of the artery wall; more in see Chronic low-grade inflammation.
Mechanism · Plaque forms, and rupture is what kills
Step three, plaque forms. Foam cells pile up into a fatty (lipid) core; smooth-muscle cells move in and secrete collagen, weaving a fibrous cap over that core. That is an atherosclerotic plaque.Step four, the plaque ruptures and becomes an acute event. A stable plaque (thick cap, small fatty core) may simply narrow the artery slowly for years. An unstable plaque (thin cap, large fatty core, strong inflammation) is prone to rupture: once it breaks, platelets gather, a clot forms and the artery is blocked on the spot, and that is a heart attack or stroke. Many heart attacks happen on plaques that narrow the artery by only 30–50%: the danger lies not in how narrow it is but in how unstable the plaque is.
This mechanism sets the logic of treatment. Lowering and means less raw material burrowing into the wall, so plaque grows more slowly and can even shrink. Statins also lower inflammation and make plaque more stable, but their benefit is broadly proportional to how far LDL falls, and how much these extra effects add is still debated. Controlling blood pressure, not smoking and controlling blood sugar protect the endothelium and let fewer particles in. So a single LDL-C number is not enough; what matters is whether plaque will grow and whether it is stable.
Chapter 4
How much diet and lifestyle can do
Swapping saturated fat for unsaturated fat and eating more soluble fiber lets the body make a few fewer harmful particles; but on its own, diet moves "bad cholesterol" by only about 10–15% in real life, so no single change solves it. If you are at high risk, or have already had a heart attack or stroke, do not wait for diet to fix it: start a statin and push lifestyle changes forward at the same time.
Stopping smoking on its own clearly lowers cardiovascular risk, and often pays off more than shaving a little more off . For most people, the cholesterol in eggs matters far less than saturated fat; what counts is the overall way of eating.
Stopping smoking on its own clearly lowers cardiovascular risk, and often pays off more than shaving a little more off . For most people, the cholesterol in eggs matters far less than saturated fat; what counts is the overall way of eating.
Numbers · How much each diet change lowers LDL
In real life, diet moves by about 10–15%. Below are the levers in order of effect size, which you can hold up against the targets in China's dietary guideline.The main lever is replacing saturated fat with unsaturated fat; replacing matters more than simply eating less fat: butter, beef and mutton fat, and coconut oil swapped for olive oil, canola oil and avocado. Each 5% of calories moved from saturated to polyunsaturated fat lowers LDL-C by about 10%. Soluble fiber (beta-glucan, from oats and barley) at 5–10 g a day lowers it by about another 5%. Spreads fortified with plant sterols, at 2 g a day, lower it by about 8–10%. Replacing other protein with 25 g of soy protein a day lowers it by about 3–5%. Nuts at 30 g a day lower it by about 5%, with (high-density lipoprotein cholesterol, the good cholesterol) unchanged. A DASH or Mediterranean way of eating lowers it by about 8–12%, and blood pressure and improve too. The evidence for dropping trans fats (hydrogenated vegetable oils) is strong: low-density lipoprotein (LDL) goes down and HDL goes up.
How to swap saturated for unsaturated fat: more in see Fats & Omega-3.
Numbers · The targets in China's dietary guideline
How much each diet change lowers is the effect size (swap this much saturated fat and LDL-C falls by this many percent). This page gives the targets: from the National Health Commission's *Dietary Guidelines for Adults with Dyslipidemia (2023 edition)*, the numbers a Chinese nutrition clinic will actually check you against.For an adult eating 1800–2000 kcal a day:
Total fat at 20–25% of calories, which is 40–55 g of fat a day from all sources, with no more than 25 g of cooking oilSaturated fat under 10% of calories; under 7% for people who already have high cholesterolDietary cholesterol under 300 mg a day; under 200 mg a day for people with high cholesterolTrans fat under 1% of calories, and no more than 2 g a dayCarbohydrate at 50–60% of calories, about 225–300 gDietary fiber at 25–40 g a day, of which 7–13 g is soluble (the soluble part is what mainly lowers LDL)500 g of vegetables a day (over half of them dark-colored), 200–350 g of fruit, plus foods that supply 25 g of soy proteinAt least 12 kinds of food a day and 25 a week
The exercise side is dosed too: 5–7 sessions a week, each at least 30 minutes at moderate or higher intensity, burning at least 200 kcal a day; people who are overweight or obese should eat 300–500 kcal less a day.
Note the figure of 25 g of soy protein: it is the same amount as the effect-size lever replacing other protein with 25 g of soy protein a day, which lowers LDL-C by 3–5%. One comes from a guideline target, the other from trial effects, and the two meet at the same number.
⚠️ This guideline also has chapters on traditional Chinese medicine pattern diagnosis and food-medicine substances; this site does not cite those parts.
nhc-2023-shiyang-dyslipidemia
In practice · Triglycerides and lifestyle
If your are high, or you already have metabolic syndrome, cutting back on sugar, fructose and alcohol brings triglycerides down fastest. Losing 5–10% of body weight lowers triglycerides by about 20–30%. Aerobic exercise plus strength training lowers triglycerides by about 15–25% and raises (the good cholesterol) by about 5–10%. High-dose fish oil ( at 2–4 g a day) can cut triglycerides by another 25–40%; more in see Fish Oil.Among the things beyond diet, stopping smoking is the most often overlooked. In cohort studies, people who quit had a 30–50% lower risk than people who kept smoking (an observed difference), which often matters more than shaving a little more off . The exercise dose is 150 minutes a week of moderate aerobic activity plus strength training twice a week. Losing 5–10% of body weight improves insulin, triglycerides and HDL. The claim that moderate drinking protects the heart does not hold: the J-shaped curve in early observational studies was not supported by Mendelian randomization studies (which group people by genes that shape how much they drink, something close to a natural randomized trial). Sleep 7–9 hours: sleep deprivation worsens insulin resistance, and fat metabolism deteriorates with it.
Clinical · When to start a drug, and eggs
Low risk with borderline : change lifestyle first for 3–6 months, then reassess. Moderate risk and still off target: alongside lifestyle, decide with your doctor whether to add a statin. High risk, or already: do not wait for diet to fix it; start a statin and push lifestyle changes forward at the same time. LDL-C ≥ 4.9 mmol/L: start a statin and get checked for familial hypercholesterolemia (FH, an inherited form of high cholesterol).The cholesterol in eggs affects blood lipids far less than saturated fat does. For most healthy people, 1–2 eggs a day is reasonable. The large cohorts do not all agree: Drouin-Chartier 2020, which combined three US cohorts with an updated , found no link between about 1 egg a day and cardiovascular disease, while Zhong 2019, pooling other US cohorts, did find a dose-related link. Both are observational evidence in people, pointing different ways, and neither should be picked alone. People with diabetes or established ASCVD should be a little more conservative (for example, no more than 5 a week), because some of them are especially sensitive to dietary cholesterol. What really matters is the overall pattern of eating, not any single food.
Blood lipid problems tend to come together with fatty liver, diabetes and high blood pressure: see Fatty Liver, Type 2 Diabetes & Prediabetes, hypertension. For the evidence on coenzyme and statin aches, see Coenzyme Q10 (Ubiquinone / Ubiquinol); red yeast rice as a stand-in does not hold up, see Red Yeast Rice.
Chapter 5
My lipid panel is off — what now?
Lipid care follows a causal chain: how high your overall risk is, how many particles there are, and how stable the plaque is. It does not follow one isolated arrow on a lab report. The same "bad cholesterol" number means completely different things in someone at low risk and someone at very high risk.
If you are at high risk, have already had a cardiovascular event, or have an extreme number, do not wait for diet to fix it. In real life, diet moves "bad cholesterol" by about 10–15%: it is the foundation, not the whole answer. With an abnormal report in hand, answer five questions in turn: how high is your risk, what is your target, lifestyle first or a drug straight away, whether to add a particle count, and what to do if a statin misses the target or cannot be tolerated.
If you are at high risk, have already had a cardiovascular event, or have an extreme number, do not wait for diet to fix it. In real life, diet moves "bad cholesterol" by about 10–15%: it is the foundation, not the whole answer. With an abnormal report in hand, answer five questions in turn: how high is your risk, what is your target, lifestyle first or a drug straight away, whether to add a particle count, and what to do if a statin misses the target or cannot be tolerated.
Clinical · Overall risk first, then the target
Ask about overall risk first; don't look at alone. Put your age, blood pressure, smoking, diabetes and any history of cardiovascular disease into a risk calculator; China-PAR is the one recommended for Chinese people. Anyone who has already had (heart attack, stroke, a stent) is at very high risk and needs no calculation: treat it as secondary prevention. Without ASCVD, the 10-year risk decides how aggressive treatment should be. The same LDL-C number means completely different things in people at low and very high risk.LDL-C targets follow the risk tier (the targets of the European ESC/EAS guideline): very high < 1.4, high < 1.8, moderate < 2.6, low < 3.0 mmol/L. The stricter the target, the more the balance tips toward a drug straight away, with lifestyle changes alongside.
Clinical · Lifestyle first, or a drug straight away
Low risk with borderline : change lifestyle first for 3–6 months, then recheck. Moderate risk and still off target: alongside lifestyle, decide with your doctor whether to add a statin. High risk, already, or LDL-C ≥ 4.9 mmol/L: do not wait for diet to fix it; start a statin and push lifestyle changes forward at the same time. People with LDL-C ≥ 4.9 should also be checked for familial hypercholesterolemia (FH, an inherited form of high cholesterol).Clinical · Testing ApoB, and when a statin falls short
For most people, is enough. In people with high , diabetes or obesity, or whose LDL-C is at target while their risk stays high, adding (apolipoprotein B, a direct count of the disease-causing particles) is more accurate. Measure , lipoprotein(a), at least once in a lifetime, so you know whether you carry an inborn genetic risk.Already on a statin but off target: raise the dose, or add ezetimibe; if that is still not enough, add a PCSK9 inhibitor. Truly intolerant (under 5% of people): switch statins, lower the dose, take it every other day, or use bempedoic acid, which does not enter muscle. Most statin muscle aches come from the nocebo effect or another problem (check vitamin D and thyroid function), so don't give up on lowering your lipids at the first ache.
Background · What lipid care is really for
The two most overlooked moves with the best return: first, stop smoking, since in cohort studies people who quit had a 30–50% lower risk, which often matters more than shaving a little more off ; second, don't expect diet alone to solve it, since in real life diet moves LDL-C by about 10–15%, the foundation rather than the whole answer.Lipid care is not about perfecting a number. It is about lowering, over the coming decades, the chance of growing an unstable plaque and having a heart attack or stroke. What you follow is the causal chain of overall risk, particle count and plaque stability, not one isolated arrow on a lab report.
Blood lipids often share roots with fatty liver, diabetes, high blood pressure and chronic inflammation: see Fatty Liver, Type 2 Diabetes & Prediabetes, hypertension, Chronic low-grade inflammation. Saturated versus unsaturated fat: see Fats & Omega-3. Supplements and alternatives: see Fish Oil, Red Yeast Rice, coq10.
References · 10
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. 10.1161/CIR.0000000000000625
- Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., et al. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111-188. 10.1093/eurheartj/ehz455
- Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013). Remnant cholesterol as a causal risk factor for ischemic heart disease. Journal of the American College of Cardiology, 61(4), 427-436. 10.1016/j.jacc.2012.08.1026
- Cholesterol Treatment Trialists' (CTT) Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376(9753), 1670-1681. 26 randomised trials, about 170,000 participants: per 1.0 mmol/L LDL reduction, major vascular events RR 0.78 (0.76-0.80), all-cause mortality RR 0.90 (0.87-0.93), mainly from fewer coronary deaths; no effect on stroke death, cancer death or cancer incidence; more versus less intensive statins lowered LDL a further 0.51 mmol/L and major vascular events a further 15%; no threshold seen within the range studied (abstract, PMID 21067804). 10.1016/S0140-6736(10)61350-5
- Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009). Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Annals of Internal Medicine, 150(12), 830-839. 10.7326/0003-4819-150-12-200906160-00006
- Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., … Nicholls, S. J. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine, 388(15), 1353-1364. 10.1056/NEJMoa2215024
- Banach, M., Serban, C., Sahebkar, A., et al. (2015). Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clinic Proceedings, 90(1), 24-34. Across 6 RCTs (302 patients), CoQ10 supplementation produced no significant improvement in statin-associated muscle pain or plasma creatine kinase. CK: 5 studies (226 participants), mean difference 11.69 U/L, P = .38; muscle pain: 5 studies (253 participants), no significant effect despite a trend; no dose-effect association (abstract, PMID 25440725). 10.1016/j.mayocp.2014.08.021
- Libby, P., Ridker, P. M., & Hansson, G. K. (2011). Progress and challenges in translating the biology of atherosclerosis. Nature, 473(7347), 317-325. 10.1038/nature10146
- Drouin-Chartier, J. P., Chen, S., Li, Y., Schwab, A. L., Stampfer, M. J., Sacks, F. M., et al. (2020). Egg consumption and risk of cardiovascular disease: three large prospective US cohort studies, systematic review, and updated meta-analysis. BMJ, 368, m513. Moderate egg intake (~1/day) was not associated with cardiovascular risk in the updated meta-analysis (~1.72M participants). 10.1136/bmj.m513
- Zhong, V. W., Van Horn, L., Cornelis, M. C., Wilkins, J. T., Ning, H., Carnethon, M. R., et al. (2019). Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA, 321(11), 1081-1095. A pooled analysis that did find a dose-dependent association — included to present the evidence honestly as mixed. 10.1001/jama.2019.1572